-
The Precision Peptide Company Inc. Signs Agreement with U.S.-Based 503A Sterile Compounding Pharmacy - Peptides to be 100% Compounded in the United States
-
The Precision Peptide Company to Exhibit as the Only Peptide Company at Dave Asprey's BEYOND Conference in Austin, Texas
-
The Precision Peptide Company Inc. Places Order for 20,000 BPC-157 Transdermal Patches
-
The Precision Peptide Company (BPC) Expands on Exclusive 50/50 Revenue Share Peptide Partnership with MMA.INC (MMA)
-
Precision Peptide's BPC-157 patch achieves 95.5% purity in lab tests
-
The Precision Peptide Company (BPC) Lead Product Achieves 95.5% Purity in Independent Lab Testing, Clearing the Industry Benchmark and Advancing Toward Commercial Launch
-
The Precision Peptide Company's Chief Scientific Officer Justin Kirkland to Be Featured on The Human Upgrade with Dave Asprey
-
MMA.INC partners with Precision Peptide in 50/50 revenue share deal
-
The Precision Peptide Company Inc. Announces Exclusive Strategic Marketing Partnership with Mixed Martial Arts Group Limited
-
Precision Peptide nears launch of needle-free BPC-157 patch
-
The Precision Peptide Company Nears Commercial Launch of Needle-Free BPC-157 Patch as Final Testing Advances
-
C$1.3 Million in Proceeds Received by The Precision Peptide Company from Warrant Exercises
-
The Precision Peptide Company Grants RSUs and Stock Options and Settles Debt
-
The Precision Peptide Company Announces Strategic Product Marketing Agreement
-
The Precision Peptide Company Applauds FDA Action Advancing Regulatory Clarity for Peptide Therapies
-
The Precision Peptide Company Announces Public Relations and Consulting Services Agreement

